VAX-001 / Entos Pharma, EpiVax, Aegis Life - LARVOL DELTA

A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults (clinicaltrials.gov) - P1/2 | N=268 | Completed | Sponsor: Entos Pharmaceuticals Inc. | Recruiting ➔ Completed | N=36 ➔ 268 | Trial primary completion date: Jul 2023 ➔ Dec 2023

Enrollment change • Trial completion • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: Entos Pharmaceuticals Inc. | Active, not recruiting ➔ Recruiting | Trial completion date: Aug 2022 ➔ Dec 2023 | Trial primary completion date: Aug 2022 ➔ Jul 2023

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults (clinicaltrials.gov) - P1/2; N=36; Active, not recruiting; Sponsor: Entos Pharmaceuticals Inc.; Recruiting ➔ Active, not recruiting; N=72 ➔ 36; Trial primary completion date: Aug 2021 ➔ Aug 2022

Clinical • Enrollment change • Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults (clinicaltrials.gov) - P1/2; N=72; Recruiting; Sponsor: Entos Pharmaceuticals Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Clinical Trial of a Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults (clinicaltrials.gov) - P1/2; N=72; Not yet recruiting; Sponsor: Entos Pharmaceuticals Inc.; Trial completion date: Aug 2021 ➔ Aug 2022

Clinical • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Clinical Trial of a Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults (clinicaltrials.gov) - P1/2; N=72; Not yet recruiting; Sponsor: Entos Pharmaceuticals Inc.; Trial primary completion date: Feb 2021 ➔ Jun 2021

Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Clinical Trial of a Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults (clinicaltrials.gov) - P1/2; N=72; Not yet recruiting; Sponsor: Entos Pharmaceuticals Inc.

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease

Entos Pharmaceuticals Announces Selection of Lead DNA Vaccine Candidates for COVID-19 and a $4.2M Award to Move Forward with Phase I/II Human Trials (PipelineReview) - "Lead candidates to be evaluated in SARS-CoV-2 animal challenge studies and advanced to human clinical trials during summer 2020; A $4.2M grant from the Canadian Institutes of Health Research (CIHR), Research Nova Scotia (RNS), and the Institute for Ageing (IA) will be used to further develop....Entos will partner with the Clinical Trials Research Center...to initiate Phase I/II human clinical trials which will evaluate the safety, tolerability, immunogenicity and efficacy of the Covigenix vaccine candidates in late July."

Grant • Licensing / partnership • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease